In that experiment, oxaliplatin administration reduced lean tissue mass that was not associated with nutrition and/or energy expenditure and increased mitochondrial superoxide [16], but with upregulation of the myopathy-linked genes Foxo3, MAFbx and Bnip3 [17]. The gene discussed is FBXO32; the disease is myopathy.